The pharmacological inhibition of PAR1 is used in patients who suffer from myocardial infarction or peripheral arterial disease to prevent cardiovascular death or cerebral ischemia, while, however, increasing the risk of bleeding, including intracranial hemorrhage [17]. The gene discussed is F2R; the disease is myocardial infarction.